Rapid Progress on Advancing Clinical Program with Commencement of Pharmacokinetic (PK) & Pharmacodynamic (PD) Cytisine Study and Completion of Enrollment in Food Effect PK Study BOTHELL, Wash and VANCOUVER, British Columbia, Oct. 4, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for…
/Read More
BOTHELL, Wash. and VANCOUVER, British Columbia, Sept. 14, 2017 /PRNewswire/ — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that it has entered into a share purchase agreement with Lincoln Park Capital Fund, LLC pursuant to which Achieve may…
/Read More
BOTHELL, Wash and VANCOUVER, British Columbia, Aug. 16, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced initiation of the Cytisine Clinical Development Program. Cytisine is an established smoking cessation treatment that has been approved and marketed in…
/Read More
Strategic Collaboration with the National Institutes of Health (NIH) Instrumental in Facilitating IND-enabling Studies BOTHELL, Wash and VANCOUVER, British Columbia, Aug. 11, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for cytisine, an established smoking cessation treatment…
/Read More
Commences Trading on NASDAQ Capital Market on August 3, 2017 Under Ticker Symbol “ACHV” BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 1, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV) today announced the closing of its previously announced merger with OncoGenex Pharmaceuticals, as a result of which the stockholders of Achieve have become the majority…
/Read More